h-7

Protein kinase inhibitor H-7 dihydrochloride(H-7 dihydrochloride) is a potent protein kinase C (PKC) inhibitor. Protein kinase inhibitor H-7 dihydrochloride (100 μM) significantly inhibits TPA (skin tumor promoter, 12-O-tetradecanoylphorbol-13-acetate) and phospholipase C-induced ODC (ornithine decarboxylase) inhibited PMA-induced promiscuity cell lysis activity.

Protein kinase inhibitor H-7 (5-(2-methylpiperazine-1-sulfonyl)isoquinoline) is a potent inhibitor of protein kinase C (PKC) with a Ki of 6 μM. Protein kinase inhibitor H-7 is also a cyclic nucleotide dependent protein kinase inhibitor.

Iso-H7 dihydrochloride is a less potent inhibitor of phosphokinase C than H-7.

H111-H7 is an inhibitor of the E3 ubiquitin ligase 27 containing the WW domain (WWP2), with a KD value of 717 nM. In a unilateral ischemia-reperfusion (UIR) mouse model, H111-H7 inhibits the expression of WWP2, restores the level of succinate dehydrogenase complex subunit C (SDHC), and slows the progression from acute kidney injury (AKI) to chronic kidney disease (CKD). H111-H7 is applicable for studying the transition from AKI to CKD.

Bombinin H7, an antimicrobial peptide originating from the skin secretions of Bombina, exhibits bactericidal activity against Bacillus megaterium Bm11 at a lethal concentration of 25.2 μM [1].

Maximin H7, an antimicrobial peptide, originates from the toad Bombina maxima [1].

BMH-7 (Histamine H4 receptor antagonist-2) is a p53 activator with antitumor activity through activation of the p53 pathway.

BMH-7 HCl is a p53 activator, showing anticancer activity through the activation of the p53 pathway.

RSH-7 is a potent dual inhibitor of BTK and FLT3, with IC50s of 47 and 12 nM, respectively.RSH-7 has antiproliferative and antitumor activities, inducing apoptosis and inhibiting BTK and FLT3 signaling.

LCH-7749944 (GNF-PF-2356) is a potent PAK4 inhibitor with an IC50 of 14.93 μM, effectively suppressing the proliferation of human gastric cancer cells by downregulating the PAK4/c-Src/EGFR/cyclin D1 pathway and inducing apoptosis.

BPH-715 inhibits the liver-stage growth of P. falciparum with an IC50 of 10 μM for P. falciparum exoerythrocytic forms in HepG2 cells.

PH-797804 is a pyridinone inhibitor of p38α (IC50: 26 nM, in a cell-free assay); 4-fold more selective versus p38β and does not inhibit JNK2.

IHCH-7086 is a compound that functions as an agonist of the 5-HT2A serotonin receptor.

IHCH-7179 is a modulator of the 5-hydroxytryptamine receptor (5-HT receptor). It acts by antagonizing the 5-HT2A receptor and activating the 5-HT1A receptor, making it applicable for research in neurological disorders.

AH-7614 (AH 7614) is a selective and potent free fatty acid receptor 4 (FFA4/GPR120) antagonist.

ACH-702 is an agent of anti-tubercular. ACH-702 is an effective, bactericidal compound with activity against many antibiotic-resistant pathogens.

AKH-7088 is a biochemical.

3β-OH-7-Oxocholenic acid is a bile acid.1 It is also a metabolite of 7β-hydroxy cholesterol in rats. Conjugated forms of 3β-OH-7-oxocholenic acid have been found in the urine of patients with Neimann-Pick disease type C.2,3 |1. Norii, T., Yamaga, N., and Yamasaki, K. Metabolism of 7β-hydroxycholesterol-4-14C in rat. Steroids 15(3), 303-326 (1970).|2. Alvelius, G., Hjalmarson, O., Griffiths, W.J., et al. Identification of unusual 7-oxygenated bile acid sulfates in a patient with Niemann-Pick disease, type C. J. Lipid Res. 42(10), 1571-1577 (2001).|3. Maekawa, M., Omura, K., Sekiguchi, S., et al. Identification of two sulfated cholesterol metabolites found in the urine of a patient with Niemann-Pick disease type C as novel candidate diagnostic markers. Mass Spectrom. (Tokyo) 5(2), S0053 (2016).

SCH-79687 is a histamine antagonist selective for the H3 subtype. This H3 antagonist may play a role in allergic rhinitis.

LH-708 is an inhibitor of cystine stone formation for treatment of cystinuria.

(aS)-PH-797804 is a selective inhibitor of p38 MAPK, demonstrating inhibitory concentration (IC50) values of 26 nM for p38α and 102 nM for p38β. This compound exhibits anti-inflammatory activity [1] [2].

Sorafenib (Bay 43-9006) is a multikinase inhibitor that targets Raf-1, B-Raf, VEGFR2, VEGFR3, VEGFR4, PDGFRβ, FLT3, c-Kit, and others (IC50=6/22/90/15/20/20/57/58 nM) with oral activity. It exhibits antitumor properties and can induce autophagy, apoptosis, and agonistic iron death.

Simvastatin (MK 733) is an HMG-CoA reductase inhibitor (Ki=0.2 nM) with oral activity. Simvastatin has hypolipidemic activity, inhibits hepatic production of cholesterol, and is also used for the prevention of cardiovascular disease.

Dinaciclib (SCH 727965) is a selective CDK inhibitor targeting CDK1, CDK2, CDK5, and CDK9 (IC50 = 3/1/1/4 nM). It exhibits potential antitumor activity by inhibiting the incorporation of thoracic glycan (dThd) DNA.